High pressure liquid chromatography (HPLC) and mass spectrum (MS) procedures.

HPLC-MS analysis was performed using an HPLC (Agilent Technologies 1200) coupled to a Thermo
Fisher LTQ mass spectrometer fitted with an electrospray ionization (ESI) source. The HPLC was fitted with a Prodigy 5µ C18 column (4.6 × 250 mm, Phenomenex) column. A solvent system of MeCN (acetonitrile) and water both containing 0.1% formic acid (v/v) was used. Samples were eluted at a flow rate 0.7 mL min HPLC-MS data were processed and deconvoluted using Xcalibur (v. 1.1) (Thermo Finnigan).
Bacterial strains and culture conditions.
Streptomyces violaceusniger DSM 4137, the producer strain of elaiophylin [1] , was grown in TSBY medium (3% tryptone soy broth, 10.3% sucrose, 0.5% yeast extract) at 30°C, 200 rpm, 250 ml flask with 30 ml medium and metal spring. E. coli strains were grown in Luria-Bertani (LB) broth (1% tryptone, 0.5% yeast extract, 0.5% NaCl) or LB agar medium (2% agar) at 37°C with 50 µg mL -1 kanamycin.
DNA manipulation.
Bacterial strains, plasmids and oligonucleotides (Invitrogen) used in this work are summarised in Tables S1 and S2 respectively. Restriction endonucleases and T4 DNA ligase were purchased from New England Biolabs. Chemicals were purchased from Sigma-Aldrich.
Plasmid DNA was isolated from an overnight culture using the Plasmid Mini Kit I (Omega BioTek)
according to the manufacturer's protocol. PCR amplifications were carried out using a Mastercycler (Eppendorf) and the Phusion High-Fidelity PCR Master Mix from New England Biolabs (for cloning), or
BioMix Red from Bioline (for screening purposes). Genomic DNA isolated from 3 d mycelium was used as template. DNA sequencing was carried out by the DNA Sequencing Facility in the Department of Biochemistry, University of Cambridge.
Expression and purification of recombinant proteins.
The expression plasmids pYJ4 and pKJW63 [3] (Table S1) were each introduced into BL21(DE3) and BL21 (DE3) plysS. A single colony was inoculated into 5 mL of LB medium containing 50 µg mL -1 kanamycin and grown overnight at 37°C, 250 rpm. 2 ml of the culture was inoculated into 1 L LB medium containing 50 µg mL -1 kanamycin and incubated at 37°C, 200 rpm until A600 reached 0.6~0.8 before adding 200 µL of 1 M isopropyl-β-D-thiogalactopyranoside and incubating at 22°C for 15 h to induce protein expression. Cells were harvested by centrifugation at 8,000 rpm for 6 min, and then resuspended in lysis buffer (50 mM tris-HCl, 0.3 M NaCl, pH 7.2) and lysed by sonication. The total lysate was centrifuged at 17,000 rpm for 25 min, and the supernatant was filtrated with 0.45 µm filter before loading on a His-Bind column (1 mL bed volume), which was pre-charged with nickel ions and equilibrated with lysis buffer. The column was washed with 10 column volumes of lysis buffer. Bound proteins were eluted with a step gradient of increasing imidazole concentration (10, 20, 40, 80, 100, 150, 200 , 250 and 500 mM in binding buffer).
Ela-TE, and DEBS-TE were eluted respectively at imidazole concentration of 20 and 80 mM. The protein solutions were concentrated, and the buffer was exchanged into 100 mM potassium phosphate buffer pH 8.2, using Amicon Ultra-4 concentrators (Millipore) fitted with a filter of 10 KD pore size. The protein yield of Ela-TE is 6 mg L -1 and the yield of DEBS-TE is 0.5 mg L -1 . The purified proteins were examined by 4 -12%
Bis-Tris Gel (Novex) analysis and HPLC-MS ( Figure S1 and Table S2 ). Protein concentration was measured by NanoDrop 1000 Spectrophotometer and determined by the mean value of three 2× dilutions samples (adjust to 1 to 6 mg mL -1 ).
Enzyme assays.
The standard assays were performed with 50 µl system of 3 mM substrate, 10% (v/v) dimethyl sulfoxide, 0.1 M potassium phosphate buffer (pH8.2), 40 µM enzyme, 5 h incubation at 20°C.
To accumulate the product 4 and 5, Ela-TE assay was scaled up to 10 ml with 50 µM enzyme, 8 mM 3b
substrate and incubated at 20°C for 12 h.
To generate product 6, both 2b and 3b substrates were used by 3 mM concentration, and the assay was scaled up to 23 ml with 40 µM enzyme and incubated at 20°C for 36 h.
Purification of the products generated from Ela-TE assay.
Enzyme was removed efficiently from the assay solution by adding 4 volume of MeCN and subsequently 10 min centrifuge. The supernatant was evaporated to remove MeCN and the remaining aqueous phase was extracted with 0.5 volume of ethyl acetate three times. The organic extract was dried and redissolved into 2 ml methanol as the sample injected to preparative-HPLC.
To purify the products 4, 5 and 6 generated from Ela-TE assay by using preparative-HPLC, water and MeCN were used as elution solvents with gradient of 30 to 95% MeCN over 30 min. UV detection was set as Sig=260 Ref=360. The retention times for 4, 5 and 6 are respectively 19.8, 28.5 and 29.9 min. The target fragments were combined and evaporated to remove MeCN. Then the remaining aqueous solution was extracted with 0.5 volume of ethyl acetate three times. Finally, 1.5 mg 5 (white powder),~0.5 mg 4 (faint yellow oil) and~0.8 mg 6 (white powder) were respectively obtained after drying the organic extract. All the products were confirmed by ESI-HR-MS and 1 H,
13
C and 2D NMR (Supporting Information 4).
Analytical ultracentrifugation (AUC) analysis.
AUC-Sedimentation velocity experiments were conducted with an Optima XL-I (Beckman Coulter) centrifuge using an An60 Ti four-hole rotor. Standard double-sector Epon centrepieces equipped with sapphire windows contained 400 μL of Ela-TE at 3 mg/ml. Interference data were acquired in the continuous mode at time intervals of 170 s and rotor speed of 45,000 rpm, at a temperature of 20°C with systematic noise subtracted, without averaging. The density and viscosity of the buffer (0.1 M potassium phosphate, pH 8.2) and the partial specific volume of the protein were calculated using Sednterp [7] . Multi-component sedimentation coefficient distributions were obtained from 128 scans by direct boundary modelling of the Lamm equation using Sedfit v.14.1 [8] . Table S1 . Plasmid construction and oligonucleotide primers.
Tables and Figures
Plasmid Protein Constructions pYJ4
Ela-TE
The DNA fragment encoding Ela-TE was amplified from genomic DNA of S. violaceusniger DSM 4137 [1] by the primer Ela-TE-S: 5' TTTAACTTTAAGAAGGAGATATACATGTCCGACCTGGCCGCGGC CAAGCA 3', Ela-TE-A: 5' ATCTCAGTGGTGGTGGTGGTGGTGCTCGGCGCCGTCGCGCTCCA G 3'. The PCR product was introduced into the NcoI and XhoI sites of pET28b(+) by isothermal assembly [9] ; The C-His-tag was introduced by the primer. pKJW63 [3] DEBS-TE The C-terminal thioesterase/cyclase DEBS-TE derived from the erythromycin PKS was expressed based on pET29b(+). Figure S3 . The production time-plot of compound 4 and 5 generated by Ela-TE from substrate 2b.
The time plot was made based on x-axis hours and y-axis peak area of extracted mass from total ion of chromatography of HPLC-MS analysis. Three parallel assays were analyzed to make each time point of the curves. Clear background was confirmed by non-enzyme control. Figure S4 . The linear dimer intermediates generated by Ela-TE from the mixture substrates.
When an equimolar mixture of 2b and 3b was incubated with Ela-TE, two linear dimer intermediates, homologous 4 and nonhomologous 7, were detected by HPLC-MS at 20.5 min retention time. Ela-TE (elaiophylin) was investigated in this work. The other three TEs respectively derived from erythromycin [6] , pikromycin [4] , and tautomycetin [5] were characterized by crystal structure. The start region of the TE domains and the active residues are all labeled. Figure S6 . The modeled structure of Ela-TE (the figure was made by PyMOL). The structures of Ela-TE is modeled based on the template of pikromycin thioesterase (c2h7xA). a) the superimposing model of pikromycin TE (orange) and Ela-TE (grey). the triplet catalytic sites of Ela-TE are indicated, blue, Ser; green, Asp; red, His. b) the model of Ela-TE surface with view of the substrate channel.
Compound Synthesis Procedures and the NMR and HRMS Confirmation.
General Remarks: All reactions, unless otherwise specified, were performed under an atmosphere of argon. Dichloromethane (DCM), toluene, triethylamine (Et3N), diisopropylethylamine (DIPEA), acetonitrile (CH3CN), methanol (MeOH), and dimethyl sulfoxide (DMSO) were treated with calcium hydride and distilled prior to use. Tetrahydrofuran (THF) and ethyl ether (Et2O) were treated with calcium hydride, distilled, and treated with sodium and benzophenone prior to use. Acetic acid (AcOH) was distilled in the presence of acetic anhydride and KMnO4. Oxalyl chloride was distilled immediately prior to use.
Camphorsulfonic acid (CSA) was recrystallized from ethyl acetate and then dried under vacuum. Other reagents were used without pretreatment. Compounds were purified by flash column chromatography using silica gel (230-400 mesh) as the stationary phase. The mobile phase used is specified for each experimental procedure. Thin-layer chromatography (TLC) on silica gel 60 and GF (5-40 μm thickness) plates was used for monitoring the progress of reactions. TLC plates were visualized using UV light and then stained with phosphomolybdic acid and heat. The maximum absorbance wavelengths (max) of infrared spectra are presented in wavenumbers (cm -1 ). The angles of deviation of the polarized light (α) are described as follows: (c [g/100 mL], solvent). High-resolution mass spectrometry (HRMS) was performed using electrospray ionization (ESI).
1 H and proton-decoupled Scheme S1. Substrate 2b synthesis.
(S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-vinylpentanoyl)oxazolidin-2-one (8) [10]
A solution of (S,E)-4-benzyl-3-(but-2-enoyl)oxazolidin-2-one (7) (8.16 mmol,
1.99 g) in 43 mL of CH2Cl2 was cooled to 78°C. A solution of dibutylboron triflate (8.91 mmol, 2.01 mL, in 7 mL of CH2Cl2) was added to the reaction dropwise via cannula. The mixture was stirred for 5 min and then triethylamine (12.4 mmol, 1.73 mL in 7 mL of CH2Cl2) was added slowly. A yellow color quickly developed as the reaction mixture was maintained at 78°C for 1 h, then warmed to 0°C, and maintained at that temperature for 20 min. The solution was recooled to 78 o C and propanal (42.5 mmol, 3.05 mL in 25 mL de CH2Cl2) was added dropwise. The solution was stirred at 78°C for 90 min and then warmed to 0°C and maintained at that temperature for 1 h. The reaction was quenched by the addition of 8.5 mL of phosphate buffer pH 7
and methanol (24.6 mL). After, a solution of methanol/H2O2 30% (2/1, 24.6 mL) was added. The reaction 
(2S,4R,5R)-4-ethyl-2-(4-methoxyphenyl)-5-vinyl-1,3-dioxane (18)
A solution of aldol adduct 8 (9.24 mmol, 2.8 g) in THF (37 mL) and MeOH (0. was added dropwise. The reaction was stirred for 45 min at this temperature. The reaction was quenched by the addition of saturated aqueous solution of sodium and potassium tartrate (40 mL). After, the reaction media was stirred for 15 min at room temperature. The solvents were removed in vacuum and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed twice with brine, dried over MgSO4, filtered, and concentrated in vacuum. The product 17 was isolated as a white solid and was used in the following step without purification. To a solution of the obtained white solid in CH2Cl2 (22.5 mL) was added dropwise at room temperature a solution of 4-methoxybenzaldehyde diethyl acetal (10.16 mmol, 2.13 g) in CH2Cl2. Catalytic amounts of CSA were added. The reaction was stirred for 3 h and was quenched with saturated aqueous solution of NaHCO3 (100 mL) and diluted with CH2Cl2 (60 mL).
The organic layer was saved and the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with brine (2 x 50 mL) and dried over MgSO4, filtered and concentrated in vacuum. The crude 
(2R,3R)-3-((4-methoxybenzyl)oxy)-2-vinylpentan-1-ol (9)
A solution of PMP acetal 18 (0.54 mmol, 132 mg) in CH2Cl2 (3 mL) was cooled to 0 o C. Then, DIBAL was added dropwise (1.35 mmol, 0.9 mL, 1.5 M solution in toluene) and the reaction was stirred for 45 min. The crude reaction was placed in a beaker containing HCl (7.8 mL, solution 0.5 M) and CH2Cl2 (7.8 mL) and the reaction mixture was stirred for 30 min at room temperature. The phases were separated and the aqueous layer was washed with CH2Cl2 (3 x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and dried over 
(2R,3R)-3-((4-methoxybenzyl)oxy)-2-vinylpentyl 4-methylbenzenesulfonate (19)
To a solution of alcohol 9 (0.37 mmol, 0.092 g) in CH2Cl2 (5 mL) were added triethylamine (1.10 mmol, 0.16 mL), DMAP (2 mol%, 0.001 g) and tosyl chloride (0.74 mmol, 0.14 g). The reaction was stirred for 4 h at room temperature. The reaction was quenched with distilled water (3 mL) and the organic layer was extracted with CH2Cl2 (3 x 25 mL). Then, the combined organic layers were washed with HCl (3 x 10 mL, 0. 
1-methoxy-4-((((3R,4S)-4-methylhex-5-en-3-yl)oxy)methyl)benzene (10)
A solution of the tosylate 19 (0.25 mmol, 0.1 g) in THF (15 mL) was cooled to 78 
(2E,4E,6S,7R)-ethyl 7-((4-methoxybenzyl)oxy)-6-methylnona-2,4-dienoate (11)
To a solution of olefin 10 (1.2 mmol, 0.282 g) in THF/acetone/buffer pH 7 (9.6 mL/9.6 mL/9.6 mL) were added OsO4 (0.12 mmol, 0. 
(2E,4E,6S,7R)-S-(2-acetamidoethyl) 7-hydroxy-6-methylnona-2,4-dienethioate (2b)
Step 1: To a solution of the acid 22 (0.25 mmol, 0.071 g) in dry DMF (2.5 mL) at room temperature were added HOBt by flash column chromatography (silica gel and hexanes/EtOAc, 70:30). Rf = 0.76 (EtOAc). We verified the presence of 1,3-dicyclohexylurea in the purified product 23. Thus, the mixture of compounds was used in the following step.
Step 2: To a stirring solution of the obtained mixture in CH2Cl2 (2.8 mL) and pH 7.0 buffer (0.3 mL) at 0°C, and DDQ (0.19 mmol, 42.6 mg) was added. The resulting mixture was stirred at room temperature for 30 min. Distilled H2O (0.9 mL) was added, the mixture was filtered and the supernatant was collected. The aqueous layer was extracted with CH2Cl2 (5 x 20 mL). The combined organic extracts were dried with anhydrous Na2SO4 and concentrated on a rotary evaporator. [ 
(R)-4-benzyl-3-((2R,3S,4S)-3-hydroxy-5-((4-methoxybenzyl)oxy)-2,4-dimethylpentanoyl)oxazolidin-2-one (13)
11]
Freshly distilled nBu2BOTf (14.52 mmol, 3.7 mL, d = 1.089 g/mL) was slowly added to a solution of chiral auxiliary (R)-4-benzyl-3-propionyloxazolidin-2-one (12) (9.68 mmol, 2.26 g) in CH2Cl2 (18.3 mL) at 10°C under an argon atmosphere. Then, DIPEA (16.5 mmol, 3 mL) was added dropwise. The temperature was reduced to 78°C and a cooled solution (ice bath) of (S)-3-((4-methoxybenzyl)oxy)-2-methylpropanal (12.6 mmol, 2.63 g) in CH2Cl2 (13 mL) was added dropwise. The reaction mixture was maintained at 78°C for 30 min and then at 10°C for 2 h. Then, phosphate buffer (22 mL) and methanol (62 mL) were added, followed by the slow addition of a 2:1 mixture of MeOH (57 mL) and H2O2 (25% aq.; 28 mL), with stirring, over 1 h at 5°C. The solvents were removed under vacuum and the crude mixture was extracted with ethyl ether (3 x 30 mL). The organic layer was washed with NaHCO3 (saturated aq.; 120 mL) and NaCl (saturated aq.; 120 mL), dried with anhydrous Na2SO4, and the solvents were evaporated under vacuum. The crude reaction product was purified by flash column chromatography to 20°C, and a solution of aldol product 13 (1.16 mmol, 510 mg) in THF (2.5 mL) was added by cannula.
The temperature was increased to 0°C and the reaction mixture was stirred for 90 min. Then, the reaction mixture was transferred by cannula to a flask containing HCl (1.0 M; 9 mL) and CH2Cl2 (9 mL) and the resulting mixture was stirred at 0°C for 90 min. The aqueous layer was extracted with CH2Cl2 (3 x 25 mL), and the organic layer was washed with NaCl (saturated aq.; 25 mL) and dried with anhydrous Na2SO4. The solvents were removed under vacuum. The crude mixture was diluted with diethyl ether (5 mL) and hexanes 
(2R,3S,4S)-3-((tert-butyldimethylsilyl)oxy)-N-methoxy-5-((4-methoxybenzyl)oxy)-N,2,4-
trimethylpentanamide (26) [11] CH2Cl2 (1,74 mL) was added to a flask containing the Weinreb amide 25
(1.43 mmol, 464 mg), and the resulting solution was cooled to 0°C. Then, 2,6-lutidine (1.86 mmol, 0.21 mL) was added, followed by TBSOTf (1.71 mmol, 0.39 mL). The reaction mixture was stirred at 0°C for 10 min and then at 25°C for 1.5 h. After this time, ethyl ether (10 mL) and cold NaHSO4 (1 M; 5 mL) were added. The reaction mixture was extracted with ethyl ether (3 x 15 mL), and the organic extracts were washed with distilled water (10 mL), NaHCO3 (saturated aq.; 15 mL), and NaCl (saturated aq.; 15 mL). The combined organic extracts were dried with anhydrous Na2SO4 and concentrated under reduced pressure. 
(4R,5S,6S)-5-((tert-butyldimethylsilyl)oxy)-7-((4-methoxybenzyl)oxy)-4,6-dimethylheptan-3-one (14)
[
(4R,5S,6S)-5-hydroxy-7-((4-methoxybenzyl)oxy)-4,6-dimethylheptan-3-one (27)
To a stirring solution of TBS ether 14 (0.11 mmol, 0.045 g) and THF (0.5 mL) in a polyethylene flask at 0°C was added a solution of HF:pyridine (0.5 mL, 60-70% solution). The reaction was stirred for 3 days at room temperature and then portions of solid NaHCO3 (500 mg) were added. The aqueous layer was extracted with EtOAc 
(4S,5S,6S)-4-ethyl-6-((S)-1-((4-methoxybenzyl)oxy)propan-2-yl)-2,2,5-trimethyl-1,3-dioxane (33)
Compound 33 was synthetized to confirm the stereochemical relationship between C3 and C5. NMR analysis of acetonide 33 confirmed the 1,3-anti stereochemical relationship between C3 and C5. [12] The diol 28 (0.15 mmol, 0.044 g) was dissolved in 2,2-dimethoxypropane (2.4 ml), followed by addition of CSA (0,012 mmol, 3 mg) at room temperature. The reaction mixture was stirred for 18 h before it was diluted with EtOAc (2 mL) and aqueous solution of saturated aqueous NaHCO3 (2 mL). The organic layer was separated and the aqueous layer was further extracted with EtOAc (3 x 10 mL). The combined organic layer was washed with brine (5 mL), dried over MgSO4, filtered and concentrated. The crude product was purified by flash chromatography (10% EtOAc/hexane) to afford the desired acetonide 33 (33 mg, 66% yield) as colorless oil. 
(2S,3S,4S,5S)-3,5-bis((tert-butyldimethylsilyl)oxy)-2,4-dimethylheptan-1-ol (29)
The compound 15 (1.0 mmol, 521 mg) was dissolved in a mixture of CH2Cl2 (19 mL) and pH 7.0 buffer (2.42 mL) at 0°C, and DDQ (1.21 mmol, 274 mg) was added. The resulting mixture was stirred at room temperature for 30 min. Distilled H2O (1.9 mL) was added, the mixture was filtered, and the supernatant was collected. The aqueous layer was extracted with CH2Cl2 (5 x 20 mL). The combined organic extracts were dried with anhydrous Na2SO4 and concentrated on a rotary evaporator. Step 1: DMSO (2.3 mmol, 0.17 mL) was added to a solution of oxalyl chloride (1.84 mmol, 0.16 mL) in CH2Cl2 (7 mL) at 78°C.
After 30 min, alcohol 29 (1.14 mmol, 460 mg) dissolved in CH2Cl2 (3.5 mL) was added. After stirring for 30 min at 78°C, triethylamine (8.4 mmol, 1.16 mL) was added and the resulting mixture was stirred for 1.5 h at 78°C. After this time, the reaction was quenched by adding NH4Cl (saturated aq., 6 mL). The phases were separated and the aqueous layer was extracted with ethyl ether (3 x 25 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, and concentrated on a rotary evaporator. The crude reaction product was used in the following step without further purification. Rf = 0.58 (5% EtOAc in hexanes).
Step 2: To a solution of (2.59 mmol, 0.56 mL) in dry THF (15.6 mL) at 4E,6S,7S,8S,9S)-7,9-bis((tert-butyldimethylsilyl)oxy)-6,8-dimethylundeca-2,4-dienoic acid (31) To a solution of the ester 16 (0.15 mmol, 0.073 g) in EtOH (5.1 mL)
at 0 o C were added H2O (2.55 mL) and an aqueous solution of KOH 10% (0.6 mL). The reaction was warmed to room temperature and stirred for 36 h. After this time, an aqueous solution of citric acid was added until pH 4 (2 mL). The reaction crude was concentrated in vacuum and diluted with EtOAc (10 mL).
The organic layer was extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuum. The crude reaction product was used in the following step without further purification. The corresponding acid was isolated as a white solid (70 mg, 99% 
(2E,4E,6S,7S,8S,9S)-S-(2-acetamidoethyl) 7,9-dihydroxy-6,8-dimethylundeca-2,4-dienethioate (3b)
Step 1 
